Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis-Reference-Cited by-同舟云学术

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis

Published:2018-10-09 Issue:1 Volume:49 Page:111-117
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Hiraoka Atsushi¹^ORCID,Kumada Takashi²,Kariyama Kazuya³,Takaguchi Koichi⁴,Itobayashi Ei⁵,Shimada Noritomo⁶,Tajiri Kazuto⁷^ORCID,Tsuji Kunihiko⁸,Ishikawa Toru⁹,Ochi Hironori¹⁰,Hirooka Masashi¹¹,Tsutsui Akemi⁴,Shibata Hiroshi¹²,Tada Toshifumi²,Toyoda Hidenori²,Nouso Kazuhiro³,Joko Kouji¹⁰^ORCID,Hiasa Yoichi¹¹^ORCID,Michitaka Kojiro¹,

Affiliation:

1. Gastroenterology Center Ehime Prefectural Central Hospital Ehime Japan

2. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu Japan

3. Department of Gastroenterology Okayama City Hospital Okayama Japan

4. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

5. Department of Gastroenterology Asahi General Hospital Asahi Japan

6. Division of Gastroenterology and Hepatology Ootakanomori Hospital Kashiwa Japan

7. Department of Gastroenterology Toyama University Hospital Toyama Japan

8. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

9. Department of Gastroenterology Saiseikai Niigata Daini Hospital Niigata Japan

10. Hepato‐biliary Center Matsuyama Red Cross Hospital Matsuyama Japan

11. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

12. Department of Gastroenterology Tokushima Prefectural Central Hospital Tokushima Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13243

Reference36 articles.

1. Global Cancer Statistics, 2002

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

4. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study;Hepatology Research;2024-07-02

2. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy;Liver International;2024-05-03

3. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma;PLOS ONE;2024-04-30

4. Field evaluation of a novel semi-quantitative point-of-care diagnostic for G6PD deficiency in Indonesia;PLOS ONE;2024-04-30

5. Systematic review of the efficacy and safety of lenvatinib in various solid tumors;Immunopharmacology and Immunotoxicology;2024-04-23